Search results

Page title matches

• Fibrate
  ...or=Barter PJ, Rye KA| title=Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism? | journal=Circulation | year= 2006 | volum A narrative review concluded that "the benefit of adding a fibrate to statin therapy in reducing the risk of cardiovascular events in patient
  4 KB (480 words) - 03:50, 26 April 2012
• Talk:Fibrate
  12 bytes (1 word) - 14:36, 3 November 2009
• Template:Fibrate/Metadata
  | pagename = Fibrate | abc = Fibrate
  998 bytes (108 words) - 14:35, 3 November 2009
• Fibrate/Definition
  111 bytes (11 words) - 14:35, 3 November 2009
• Fibrate/Related Articles
  343 bytes (37 words) - 14:39, 3 November 2009

Page text matches

• Template:Fibrate/Metadata
  | pagename = Fibrate | abc = Fibrate
  998 bytes (108 words) - 14:35, 3 November 2009
• Fibrate
  ...or=Barter PJ, Rye KA| title=Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism? | journal=Circulation | year= 2006 | volum A narrative review concluded that "the benefit of adding a fibrate to statin therapy in reducing the risk of cardiovascular events in patient
  4 KB (480 words) - 03:50, 26 April 2012
• Talk:Fenofibrate
  ...o be some synergies in lowering cardiovascular risk, perhaps also with the fibrate potentiating the TZD role in decreasing insulin resistance by lowering circ
  755 bytes (113 words) - 08:45, 28 May 2008
• Gemfibrozil
  ...ide]] levels, with variable effects on [[cholesterol]]. Gemfibrozil is a [[fibrate]] derivative similar to [[bezafibrate]], [[clofibrate]], and [[procetofen]]
  2 KB (208 words) - 09:09, 3 November 2009
• Antilipemic agent
  ...Schelleman H, Bilker WB, Brensinger CM, Wan F, Yang YX, Hennessy S| title=Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk. |
  2 KB (227 words) - 07:30, 11 May 2010
• Anticholesteremic agent
  [[Fibrate]]s (fibric acid derivatives)
  3 KB (339 words) - 09:11, 24 February 2010
• Cytochrome P-450
  ...=Schelleman H, Bilker WB, Brensinger CM, Wan F, Yang YX, Hennessy S| title=Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk. | j ...Schelleman H, Bilker WB, Brensinger CM, Wan F, Yang YX, Hennessy S| title=Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk. |
  22 KB (2,960 words) - 17:35, 10 February 2024
• User:Howard C. Berkowitz/PPAR
  ...}}</ref> These agents, [[pharmacology|pharmacologically]] related to the [[fibrate]]s were discovered in the early [[1980s]]. When it turned out that PPARs pl ...proliferator-activated receptor alpha|PPAR-alpha]] is the main target of [[fibrate]] [[medication|drugs]], a class of amphipathic carboxylic acids ([[clofibra
  15 KB (1,980 words) - 03:57, 22 November 2023
• Warfarin
  ...me="pmid20103024">{{cite journal| author=Schelleman H ''et al.'' | title=Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk. |
  52 KB (7,136 words) - 22:53, 6 April 2014